Jonathan Rosenberg, MD

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center

Articles by Jonathan Rosenberg, MD

Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares their hopes for the future of bladder cancer treatment.
View More
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares treatment sequencing decisions based on a few patient scenarios.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel shares lessons learned from the phase THOR study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the CheckMate 901 study results.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discusses the "buzz" around the EV-302 study.
Peter O'Donnell, MDRoundtable | November 17, 2023
The panel discussed continued unmet needs and challenges for patients with urothelial cancer.
Jonathan Rosenberg, MDAdvanced Urothelial Carcinoma | May 9, 2023
Dr. Rosenberg discusses EV plus pembrolizumab, how the combination is being investigated in clinical trials, and toxicity.